Nuo Therapeutics director exercises options, gets grant

Nuo Therapeutics director and 10% owner Scott M. Pittman reported a compensation-related option exercise and new option grant.

Rhea-AI Filing Summary

Nuo Therapeutics director and 10% owner Scott M. Pittman reported a compensation-related option exercise and new option grant. He exercised options for 40,000 shares of common stock at $1.00 per share. In a net share settlement, the issuer withheld 39,604 shares at a closing price of $1.01 to cover the exercise cost, and Pittman received 396 net shares.

After the transactions, he directly owns 5,440,000 shares of common stock. He also received a new grant of options for 30,000 shares with an exercise price of $1.01 per share that fully vest as of June 30, 2027 and expire on June 29, 2036. These actions reflect routine equity compensation and tax withholding rather than open-market trading.

Insider Trade Summary

40,000 shares exercised/converted

Exercise 4 txns

Insider Pittman Scott M.

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Exercise	Option to purchase common stock	40,000	$0.00	$0.00
Exercise	Common Stock	40,000	$1.00	$40K
Exercise Price or Tax Liability	Common Stock	39,604	$1.01	$40K
Grant/Award	Option to purchase common stock	30,000	$0.00	$0.00

Holdings After Transaction: Option to purchase common stock — 30,000 contracts (Direct); Common Stock — 5,400,396 shares (Direct)

Footnotes (3)

1. F1. Represents a net exercise of outstanding stock options. The reporting person received 396 shares of common stock on the net exercise of option to purchase 40,000 shares of common stock. The issuer withheld 39,604 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.
2. F2. 15,000 options exercisable on 07/01/2016 and 25,000 options exercisable on 01/01/2017.
3. F3. The options fully vest as of June 30, 2027.

Key Figures

Options exercised: 40,000 shares Exercise price: $1.00 per share Shares withheld: 39,604 shares +5 more

8 metrics

Options exercised 40,000 shares Common stock options exercised on June 30, 2026 at $1.00

Exercise price $1.00 per share Price for exercised 40,000-share option

Shares withheld 39,604 shares Withheld to pay exercise cost using $1.01 closing price

Net shares received 396 shares Net from 40,000-share option after withholding

Shares owned after 5,440,000 shares Direct common stock holdings after transactions

New option grant 30,000 options Options to purchase common stock at $1.01

New option vesting June 30, 2027 Date options for 30,000 shares fully vest

New option expiration June 29, 2036 Expiration date of 30,000-share option grant

Key Terms

net exercise, stock options, derivative security, grant, award, or other acquisition, +1 more

5 terms

net exercise financial

"Represents a net exercise of outstanding stock options."

A net exercise is a way to convert stock options into shares without paying cash up front: instead of handing over money to buy the optioned shares, the holder receives only the number of shares equal to the option’s value after the company withholds a portion of shares to cover the exercise price and taxes. It matters to investors because it changes how many new shares are issued, affects dilution of existing shareholders, and alters company cash flow compared with a cash exercise.

stock options financial

"Represents a net exercise of outstanding stock options."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

grant, award, or other acquisition financial

"Grant, award, or other acquisition"

Option to purchase common stock financial

"Option to purchase common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Scott M. Pittman report for Nuo Therapeutics (AURX)?

Scott M. Pittman reported exercising stock options for 40,000 Nuo Therapeutics shares and receiving a new 30,000-share option grant. The exercise was settled mostly through share withholding to cover the cost, resulting in 396 additional shares owned directly.

How many Nuo Therapeutics (AURX) shares does Scott M. Pittman hold after these transactions?

Following the reported transactions, Scott M. Pittman directly holds 5,440,000 shares of Nuo Therapeutics common stock. This figure reflects the net result of his 40,000-share option exercise and related tax and exercise-price share withholding on June 30, 2026.

Was Scott M. Pittman’s Nuo Therapeutics transaction an open-market sale?

The Form 4 shows no open-market sale. Instead, 39,604 shares were withheld by the issuer to pay the option exercise cost using a $1.01 closing price, leaving Pittman with 396 net shares from a 40,000-share option exercise.

What are the terms of Scott M. Pittman’s new Nuo Therapeutics stock option grant?

Pittman received options for 30,000 Nuo Therapeutics shares at a $1.01 exercise price. The options fully vest as of June 30, 2027 and expire on June 29, 2036, providing long-dated equity-based compensation tied to future company performance.

What does the net exercise of 40,000 Nuo Therapeutics options mean for shareholders?

The net exercise converted 40,000 options into common shares, but 39,604 were withheld to fund the exercise using a $1.01 closing price. Pittman received 396 new shares, indicating a routine compensation and tax-related event rather than discretionary market selling.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 09:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pittman Scott M.

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TEXAS 77054

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		M		40,000	A	$1	5,440,000	D
Common Stock	06/30/2026		F(1)		39,604	D	$1.01	5,400,396	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$1	06/30/2026		M			40,000	01/01/2017(2)	06/30/2026	Common Stock	40,000	$0	0	D
Option to purchase common stock	$1.01	06/29/2026		A		30,000		06/30/2027(3)	06/29/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. Represents a net exercise of outstanding stock options. The reporting person received 396 shares of common stock on the net exercise of option to purchase 40,000 shares of common stock. The issuer withheld 39,604 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01.

2. 15,000 options exercisable on 07/01/2016 and 25,000 options exercisable on 01/01/2017.

3. The options fully vest as of June 30, 2027.

	/s/ David Jorden, attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)